Toni Choueiri, MD discusses a novel HIF-2alpha inhibitor called casdatifan
Dana-Farber
February 26, 2025
Results show it was well-tolerated and showed promising early clinical activity in heavily pretreated patients with clear cell renal cell carcinoma.